Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.

Seth Y Ablordeppey, Ramazan Altundas, Barbara Bricker, Xue Y Zhu, Eyunni V K Suresh Kumar, Tanise Jackson, Abdul Khan, Bryan L Roth, Seth Y. Ablordeppey, Ramazan Altundas, Barbara Bricker, Xue Y. Zhu, Eyunni V.K. Suresh Kumar, Tanise Jackson, Abdul Khan, Bryan L. Roth

文献索引：Bioorg. Med. Chem. 16 , 7291-301, (2008)

全文：HTML全文

摘要

The synthesis and exploration of novel butyrophenones have led to the identification of a diazepane analogue of haloperidol, 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one (compound 13) with an interesting multireceptor binding profile. Compound 13 was evaluated for its binding affinities at DA subtype receptors, 5HT subtype receptors, H-1, M-1 receptors and at NET, DAT, and SERT transporters. At each of these receptors, compound 13 was equipotent or better than several of the standards currently in use. In in vivo mouse and rat models to evaluate its efficacy and propensity to elicit catalepsy and hence EPS in humans, compound 13 showed similar efficacy as clozapine and did not produce catalepsy at five times its ED(50) value.